SCHEMBL3646830

SCHEMBL3646830

FC(F)(F)c1cccc(SCCCl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
GAA P10253 3/20 0.46
ALDH1A1 P00352 2/20 0.46
POLB P06746 2/20 0.46
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KIF11 P52732 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
IDO1 P14902 1/20 0.39
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11832467 0.85 KDM4E (0.51) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL11449929 0.84 KIF11 (0.57) KDM4EGAAALDH1A1POLBATM
SCHEMBL12879674 0.82 GAA (0.52) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL3646958 0.82 KDM4E (0.49) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL27722503 0.79 KDM4E (0.53) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL9621723 0.78 KDM4E (0.49) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL10494902 0.78 KDM4E (0.46) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL2647186 0.78 KDM4E (0.51) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL18680739 0.78 ALDH1A1 (0.54) KDM4EGAAALDH1A1POLBMAPT
SCHEMBL27870807 0.78 KDM4E (0.55) KDM4EGAAALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084470-B2 Substituted nicotinamide compounds and uses thereof GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
EP-2188258-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICAL PRODUCTS Grünenthal GmbH (DE) 2010-05-26 EP disclosed
WO-2009036938-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICAL PRODUCTS Grünenthal GmbH (DE) 2009-03-26 WO disclosed
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF GRUENENTHAL GMBH (DE) 2009-03-19 US disclosed
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 KDM4E 1577/4885GAA 3750/4885ALDH1A1 812/4885
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF NNT, NAMPT, NADK KDM4E 2156/4885GAA 1201/4885ALDH1A1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.